<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of myasthenia gravis in pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of myasthenia gravis in pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of myasthenia gravis in pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shawn J Bird, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irene P Stafford, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary A Dildy, III, MD, FACOG, CPHQ, CPPS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myasthenia gravis (MG) is an autoimmune disorder characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles. Affected patients (most often young females and older males) usually present with fatigable weakness after repetitive muscle use.</p><p>This topic will discuss the effect of pregnancy on MG and management of MG in pregnancy. It will also briefly review clinical and treatment issues related to MG that are discussed in greater detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5153.html" rel="external">"Pathogenesis of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5168.html" rel="external">"Differential diagnosis of myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL ASPECTS</span><span class="headingEndMark"> — </span>MG is a relatively uncommon autoimmune disorder characterized by weakness and fatigability of skeletal muscles due to dysfunction of the neuromuscular junction. It can occur at any age, but there is a bimodal distribution to the age of onset with an early peak in the second and third decades (female predominance) and a late peak in the sixth to eighth decade (male predominance). (See  <a class="medical medical_review" href="/z/d/html/5153.html" rel="external">"Pathogenesis of myasthenia gravis"</a>.)</p><p>There are two clinical forms of myasthenia: ocular and generalized. In ocular MG (OMG), the weakness is limited to the eyelids and extraocular muscles. In generalized MG disease, the weakness commonly affects the ocular muscles, but it also involves a variable combination of bulbar, limb, and respiratory muscles. (See  <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/5242.html" rel="external">"Ocular myasthenia gravis"</a>.)</p><p>More than 50 percent of patients with MG present with ocular symptoms of ptosis and/or diplopia. Of those who present with ocular manifestations, about half will remain purely ocular. About 15 percent of patients present with bulbar symptoms. These include fatigable chewing, dysphagia, and dysarthria. Less than 5 percent present with proximal limb weakness alone. Involvement of the muscles of respiration produces the most serious symptoms in MG, such as respiratory insufficiency and pending respiratory failure, termed myasthenic crisis. (See  <a class="medical medical_review" href="/z/d/html/5125.html" rel="external">"Myasthenic crisis"</a>.)</p><p>Many patients with acetylcholine receptor (AChR) antibody-positive MG have thymic abnormalities, including hyperplasia in 60 to 70 percent and thymoma in 10 to 12 percent.</p><p>In all patients with clinically suspected MG, the diagnosis should be confirmed, if possible, by immunologic and/or electrodiagnostic testing  (<a class="graphic graphic_table graphicRef77349" href="/z/d/graphic/77349.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">EFFECT OF PREGNANCY</span><span class="headingEndMark"> — </span>Pregnancy has a variable effect on the course of MG [<a href="#rid1">1-3</a>]. However, patients with MG that is under good control before pregnancy can be reassured that they are likely to remain stable throughout pregnancy, although a small proportion may have worsening in the postpartum period [<a href="#rid4">4</a>]. For patients with active MG before pregnancy, flares are most likely to occur in the first trimester and the postpartum period. Some patients may be diagnosed with MG after developing initial symptoms during pregnancy [<a href="#rid5">5-7</a>].</p><p>In a metanalysis including over 32 studies and 824 pregnant patients where an MG exacerbation occurred in 34 percent, remission occurred in 20 percent, and no change in disease was reported by 48 percent. Postpartum exacerbations were noted in 30 percent of all patients. In addition, myasthenic crisis occurred during pregnancy in 8 percent and in the postpartum period in 8 percent. Similar findings have been reported in other studies as well [<a href="#rid1">1,5,8-12</a>].</p><p>As already noted, the first trimester and the acute postpartum period are times of highest risk for exacerbation [<a href="#rid13">13</a>]. Mortality risk of the mother with MG is inversely proportional to the duration of disease, with the highest risk being within the first year after disease onset [<a href="#rid14">14</a>]. Myasthenic flare may occur after therapeutic abortion secondary to the stress of surgery, but it usually remits following spontaneous abortion [<a href="#rid5">5,8</a>].</p><p class="headingAnchor" id="H3268874826"><span class="h1">NEONATAL MYASTHENIA GRAVIS</span><span class="headingEndMark"> — </span>Transient neonatal MG develops in 10 to 20 percent of infants born to myasthenic mothers due to transplacental passage of IgG anti-acetylcholine receptor antibodies (AChR-Ab). Though definitive data are lacking, a small retrospective study found no correlation between neonatal MG and the maternal IgG anti-AChR titer [<a href="#rid15">15</a>]. In addition, a small prospective study found that the duration of maternal disease and medication usage for MG were not associated with the occurrence of neonatal MG [<a href="#rid16">16</a>].</p><p>Among mothers with a child affected by transient neonatal MG, the risk of recurrence with subsequent pregnancies is approximately 75 percent. (See  <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">"Neuromuscular junction disorders in newborns and infants", section on 'Neonatal myasthenia gravis'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">PREPREGNANCY PLANNING</span><span class="headingEndMark"> — </span>The following general principles apply to the management of patients with MG during pregnancy [<a href="#rid4">4,13,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with MG, pregnancy should be planned well in advance with multidisciplinary management including, where available, maternal-fetal medicine specialists with expertise for managing high-risk, complicated pregnancies. (See  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Care provider'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prepregnancy counseling should include a discussion concerning safety of therapies for MG, with avoidance or discontinuation of known teratogenic medications (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil). (See <a class="local">'Symptomatic therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thymectomy in the year prior to conception is unlikely to result in clinical remission of MG in the mother before pregnancy, and its impact on the risk of neonatal MG is undetermined. Most experts advise young patients to proceed with thymectomy as soon as possible, with the exception of those who are already pregnant. In such cases, thymectomy should be performed when feasible after pregnancy [<a href="#rid4">4</a>].</p><p></p><p>Retrospective analysis of data from the Medical Birth Registry of Norway found that neonates of mothers with MG who had undergone thymectomy were less likely to develop neonatal MG than those born to mothers without thymectomy (9/72 [13 percent] versus 17/63 [27 percent], relative risk 0.4, 95% CI 0.16-0.94) [<a href="#rid18">18</a>]. These results suggest that thymectomy has a protective effect against neonatal MG. Of note, 25 of the 41 thymectomized mothers had undergone thymectomy an average of five years before the first birth, allowing more time for the benefit of thymectomy to accumulate. However, the strength of this study is limited by the retrospective design, lack of randomization and blinding, and wide confidence intervals.</p><p>It is important to note that the beneficial effects thymectomy are delayed for all patients and may take years to accrue, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5127.html" rel="external">"Role of thymectomy in patients with myasthenia gravis", section on 'Generalized AChR-positive myasthenia'</a>.)</p><p class="headingAnchor" id="H2009410266"><span class="h1">MANAGEMENT DURING PREGNANCY</span></p><p class="headingAnchor" id="H1707685548"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Baseline and surveillance clinical evaluations of pregnant patients with MG includes assessment of neurologic status and risks for neurologic deterioration.</p><p class="bulletIndent1"><span class="glyph">●</span>Initial evaluation of the pregnant patient with MG includes assessment of baseline motor strength, respiratory status, and pulmonary function tests. Cardiac status should be followed with electrocardiograms, since rare occurrences of focal myocardial necrosis have been recorded in patients with MG [<a href="#rid19">19,20</a>]. Thyroid function tests should be performed since there is an association between MG and other autoimmune diseases [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All infections should be treated promptly. In one study of 65 pregnant females with MG, four who had underlying infection (pyelonephritis, endometritis, or mastitis) all developed MG exacerbations [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complaints of dyspnea or cough call for prompt evaluation of possible myasthenic flare with diaphragm and respiratory muscle weakness [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical and emotional stress can exacerbate MG.</p><p></p><p class="headingAnchor" id="H3220538814"><span class="h2">Medications for myasthenia gravis</span><span class="headingEndMark"> — </span>Although the normal physiologic changes associated with pregnancy may affect the course of MG, the treatment of MG in pregnancy is similar to that in patients who are not pregnant. (See  <a class="medical medical_review" href="/z/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a>.)</p><p>A number of medications may exacerbate weakness in the myasthenic patient and should be avoided whenever possible  (<a class="graphic graphic_table graphicRef100362" href="/z/d/graphic/100362.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H8"><span class="h3">Symptomatic therapy</span><span class="headingEndMark"> — </span>Acetylcholinesterase inhibitors such as <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a> are the standard first-line symptomatic treatment for MG, including during pregnancy [<a href="#rid4">4</a>]. Dose adjustment may be required in pregnancy as a result of increased renal clearance, expanded maternal blood volume, delayed gastric emptying, and frequent emesis [<a href="#rid22">22</a>]. Increasing the dose of pyridostigmine should first be accomplished by decreasing the interval of administration, followed by increasing the dose if symptoms persist. (See  <a class="medical medical_review" href="/z/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Initial symptomatic therapy'</a>.) </p><p>Intravenous acetylcholinesterase inhibitors may produce uterine contractions and should not be used during pregnancy prior to delivery [<a href="#rid17">17</a>]. During labor, however, anticholinesterase medications should be administered parenterally to avoid erratic gastrointestinal absorption. (See <a class="local">'Labor and delivery'</a> below.)</p><p class="headingAnchor" id="H3891359048"><span class="h3">Immunomodulatory therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is the immunomodulatory agent of choice in pregnancy [<a href="#rid4">4</a>]. In addition to glucocorticoids, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may be used if anticholinesterases fail to control MG exacerbations [<a href="#rid4">4</a>]. These medications have been well studied in pregnancy, mainly in transplant recipients and patients with autoimmune diseases other than MG and have been found to be relatively safe [<a href="#rid23">23,24</a>]. However, high doses of cyclosporine and azathioprine have been linked to spontaneous abortion, preterm labor, low birth weight, chromosomal damage [<a href="#rid2">2,23,24</a>], and hematologic suppression; they should be reserved for pregnant patients who are not controlled, cannot tolerate glucocorticoids, or have significant comorbidities that may worsen with glucocorticoid administration [<a href="#rid2">2,23-25</a>]. The risk of continuing these medications in high doses should be weighed against the benefit of controlling myasthenic symptoms. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> increase the risk of teratogenicity and should not be used in pregnancy [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a> and  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis"</a>.)</p><p>Caution should be exercised when initiating therapy with glucocorticoids, since a transient worsening of MG may occur. Glucocorticoids may also produce carbohydrate intolerance, especially during pregnancy. Even though there are no teratogenic effects from glucocorticoids, pregnant patients with MG who rely on these medications should be maintained on the lowest possible dose [<a href="#rid2">2,19</a>]. The use of glucocorticoids to treat MG, including dosing and tapering schedules, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Glucocorticoids'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MuSK antibody positive MG </strong>– Patients with anti-acetylcholine receptor antibodies (AChR-Ab)-negative MG who are muscle-specific receptor tyrosine kinase (MuSK) antibody positive share most of the clinical manifestations of generalized myasthenia but are generally less responsive to acetylcholinesterase inhibitors. For patients with MuSK antibody-associated MG, treatment with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, plasma exchange, or other immunomodulatory therapies may be required [<a href="#rid6">6</a>]. For those with severe and progressive MG, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be used as a first line immunomodulatory therapy. However, the data are limited for rituximab use during conception and pregnancy; the risks and benefits must be weighed carefully and discussed with the patient. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a> and  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myasthenic crisis </strong>– Plasmapheresis and high-dose intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> are safe in pregnancy and have also been used for myasthenic crisis with variable results [<a href="#rid2">2,5,13,19,26</a>]. These interventions should be reserved for cases where conventional therapy has failed and developing respiratory failure or profound dysphagia and weakness threatens the mother and fetus [<a href="#rid11">11,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/5125.html" rel="external">"Myasthenic crisis", section on 'Rapid therapies'</a>.)</p><p></p><p>The data are limited regarding the use of infusion therapies during pregnancy for generalized, acetylcholine receptor-positive MG patients. These agents include efgartigimod, <a class="drug drug_general" data-topicid="119990" href="/z/d/drug information/119990.html" rel="external">ravulizumab</a>, and <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a>. (See  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Eculizumab'</a> and  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Ravulizumab'</a> and  <a class="medical medical_review" href="/z/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Efgartigimod'</a>.)</p><p class="headingAnchor" id="H1911505001"><span class="h2">Patients with preeclampsia and eclampsia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">Magnesium sulfate</a> is commonly administered in contemporary obstetrics for management of preeclampsia/eclampsia and preterm labor but is <strong>contraindicated</strong> in patients who have MG since it can precipitate a severe myasthenic crisis  (<a class="graphic graphic_table graphicRef100362" href="/z/d/graphic/100362.html" rel="external">table 2</a>) [<a href="#rid28">28,29</a>]. Severe hypertension can be treated with <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a> or <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, while beta blockers and calcium channel blockers should be avoided if possible [<a href="#rid28">28,29</a>]. <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">Levetiracetam</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a> can be used for seizure prophylaxis, whereas <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> can potentially exacerbate weakness and is therefore reserved for refractory seizures [<a href="#rid20">20,22</a>]. The patient with preeclampsia and myasthenia on high-dose glucocorticoids is at high risk for pulmonary edema and should be monitored closely. In addition, decreased urine output is often found in patients with preeclampsia and may require dosing modifications in order to avoid toxicity [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Fetal assessment</span><span class="headingEndMark"> — </span>The development of fetal abnormalities related to transplacental passage of IgG AChR-Abs is a major concern during pregnancy in mothers with MG. (See  <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">"Neuromuscular junction disorders in newborns and infants", section on 'Neonatal myasthenia gravis'</a>.)</p><p>Assessment of fetal well-being may include the nonstress test or biophysical profile. Methods of fetal assessment are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment", section on 'Fetal assessment techniques'</a> and  <a class="medical medical_review" href="/z/d/html/409.html" rel="external">"Nonstress test and contraction stress test"</a>.)</p><p>The perception of fetal movement may be altered in patients with MG. Continuous fetal monitoring is indicated during a myasthenic crisis if the fetus is at a viable gestational age (eg, at least 23 menstrual weeks of gestation) given the high risk of maternal and fetal hypoxia.</p><p>Abnormal sonographic findings in affected pregnancies may include polyhydramnios due to impaired fetal swallowing [<a href="#rid30">30,31</a>]. Decreased fetal movement and breathing have also been described [<a href="#rid30">30</a>].</p><p>Fetal arthrogryposis multiplex congenita is the most severe finding in the fetus with neonatal MG; lack of generalized fetal movement and diaphragmatic excursion may rarely produce joint contractures and pulmonary hypoplasia [<a href="#rid30">30,32</a>]. Several studies describe a direct relationship between high maternal titers of AChR-Abs and fetal arthrogryposis multiplex congenital [<a href="#rid30">30,32</a>]. Whereas ultrasound may be able to detect these abnormalities during the antepartum period, its utility for predicting clinical outcome is not well defined.</p><p class="headingAnchor" id="H10"><span class="h1">LABOR AND DELIVERY</span></p><p class="headingAnchor" id="H3000070567"><span class="h2">Mode of delivery</span><span class="headingEndMark"> — </span>Spontaneous vaginal delivery is the objective and should be encouraged [<a href="#rid4">4</a>]. Cesarean delivery should be reserved for the usual obstetrical indications. Appropriate steps should be taken to circumvent the effects of maternal fatigue on delivery, since stress and exertion can precipitate a myasthenic crisis [<a href="#rid21">21</a>]. The first stage of labor is not affected by MG because the uterus is composed of smooth muscle and lacks the postsynaptic acetylcholine receptor. In contrast, the second stage of labor may be affected because the voluntary striated muscles used during expulsive efforts may easily weaken. Excessive maternal fatigue may result. Operative vaginal delivery may reduce maternal fatigue and weakness. In a systematic review that included 824 pregnancies, spontaneous vaginal delivery was performed for 56 percent of births, operative vaginal delivery for 10 percent, and cesarean birth represented only 3 percent of deliveries [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1955903800"><span class="h2">Monitoring and management of neuromuscular status</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anesthesiology consultation</strong> – Consultation with an anesthesiologist before labor is recommended, since patients with MG who undergo general anesthesia may be at increased risk for requiring mechanical ventilation [<a href="#rid34">34,35</a>]. Selection of anesthetic technique is dependent on several factors. Regional anesthesia is recommended for mild to moderate disease when vaginal delivery is anticipated, allowing for adequate anesthesia if vacuum or forceps are needed; it also can reduce fatigue associated with the second stage of labor. General endotracheal anesthesia is recommended for the patient with severe disease and compromised respiratory or bulbar status [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Neuromuscular blocking agents should be avoided if neuromuscular monitoring and <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">sugammadex</a> are unavailable since patients with MG have altered acetylcholinesterase activity. Due to the relative resistance to <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>, larger doses are often required leading to a prolonged block [<a href="#rid19">19</a>]. Patients with MG are more sensitive to inhaled anesthetics including <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">desflurane</a>, halothane, and <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">isoflurane</a> [<a href="#rid19">19,36</a>]. </p><p></p><p class="bulletIndent1">Sedatives, opioids, and tranquilizers can potentiate respiratory depression in this population and should be administered judiciously. When using opioids or other sedatives for pain control, pulse oximetry and frequent assessment of respiratory rate is recommended. Nonsteroidal anti-inflammatory drugs such as <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a> <a class="drug drug_general" data-topicid="10027" href="/z/d/drug information/10027.html" rel="external">tromethamine</a> may also be used for postpartum or postoperative pain.</p><p></p><p class="bulletIndent1">During labor, anticholinesterase medications should be administered parenterally to avoid erratic gastrointestinal absorption. The dose of <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a> is individualized based on patient symptoms. The parenteral dose of pyridostigmine is equivalent to one-thirtieth of the patient's oral dose.</p><p></p><p class="bulletIndent1">The periprocedural anesthetic management of patients with MG is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/94256.html" rel="external">"Anesthesia for the patient with myasthenia gravis", section on 'Anesthesia management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory status</strong> – The maternal respiratory status (respiratory rate, pulse oximetry) should be monitored carefully because stress and fatigue associated with labor and delivery may precipitate worsening of disease. Another issues is that chronic glucocorticoid therapy can suppress the hypothalamic-pituitary-adrenal axis and lead to adrenal insufficiency during times of stress such as labor and delivery. Therefore, some experts suggest that patients on long-term glucocorticoids who take <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent at a dose &gt;7.5 mg/day should receive stress-dose <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> during the intrapartum period [<a href="#rid17">17</a>]. Other experts use somewhat different thresholds to determine the need for glucocorticoid coverage based upon the patient's history of glucocorticoid intake and likelihood of hypothalamic-pituitary-adrenal axis suppression, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Pregnant patients with MG have an increased incidence of preterm labor and birth in some studies [<a href="#rid37">37,38</a>], although this is not confirmed by other studies [<a href="#rid8">8</a>]. In one review, the rates of preterm birth occurring prior to 37 and 34 weeks gestation were 12 and 4 percent, respectively [<a href="#rid33">33</a>].</p><p>Estimates of perinatal mortality rates for infants born of patients with MG vary widely [<a href="#rid1">1,37</a>]. In a retrospective population study, perinatal mortality was not significantly higher among 127 births by Norwegian females with MG compared with those of a reference group without MG (2.4 versus 1.4 percent) [<a href="#rid37">37</a>]. However, females with MG had a significantly higher risk of delivery complications than the reference group (41 versus 33 percent); the most common complication was premature rupture of membranes. Cesarean deliveries were also performed more frequently in females with MG (17 versus 9 percent of deliveries); half were elective. In contrast, a population based study from Taiwan found no significant differences between pregnant patients with MG and controls for the risk of delivery complicated by low birth weight, small for gestational age, or cesarean delivery [<a href="#rid39">39</a>].</p><p>An earlier study found that the death rate due to fetal anomalies was higher in the myasthenic population compared with the normal population (18 versus 2.2 per 1000 live births) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2987494363"><span class="h1">POSTPARTUM MANAGEMENT</span></p><p class="headingAnchor" id="H1269119899"><span class="h2">Monitoring for neonatal MG</span><span class="headingEndMark"> — </span>All infants of myasthenic mothers should be observed and monitored in a special care nursery for the first 48 to 72 hours of life for any evidence of weakness caused by transient neonatal MG [<a href="#rid13">13</a>]. Symptoms of respiratory distress, poor feeding, and flaccid tone can appear within hours after birth and may persist for up to three months.</p><p class="headingAnchor" id="H12"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>Glucocorticoids can be used safely in lactation. Anticholinesterase drugs are found in breast milk in low levels and are therefore considered safe in lactation unless high doses are required [<a href="#rid2">2</a>]. Breastfeeding may continue along with the use of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, or plasma exchange. Breastfeeding is not recommended for patients with MG taking <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid13">13,40</a>].</p><p class="headingAnchor" id="H3089109242"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117890.html" rel="external">"Society guideline links: Myasthenia gravis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122676.html" rel="external">"Society guideline links: Thymomas and thymic carcinomas"</a>.)</p><p class="headingAnchor" id="H377884889"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86724.html" rel="external">"Patient education: Myasthenia gravis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness and fatigability of skeletal muscles due to dysfunction of the neuromuscular junction. The diagnosis is confirmed by immunologic and/or electrodiagnostic testing  (<a class="graphic graphic_table graphicRef77349" href="/z/d/graphic/77349.html" rel="external">table 1</a>). (See <a class="local">'Clinical aspects'</a> above.)</p><p></p><p class="bulletIndent1">Transient neonatal MG develops in 10 to 20 percent of infants born to myasthenic mothers due to transplacental passage of IgG anti-acetylcholine receptor antibodies (AChR-Abs). (See <a class="local">'Neonatal myasthenia gravis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of pregnancy on MG </strong>– Pregnancy has a variable effect on the course of MG. The first trimester and the acute postpartum period are times of highest risk for exacerbation. (See <a class="local">'Effect of pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prepregnancy planning </strong>– For patients with MG, pregnancy should be planned well in advance with multidisciplinary communication among specialists to optimize the clinical management of MG and to minimize risks to the fetus. (See <a class="local">'Prepregnancy planning'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment during pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MG treatment </strong>– Anticholinesterase agents such as <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a> are the standard first-line symptomatic treatment for MG. Dose adjustment may be required in pregnancy. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is the immunomodulatory agent of choice in pregnancy. (See <a class="local">'Medications for myasthenia gravis'</a> above.)</p><p></p><p class="bulletIndent2">The use of other immunomodulatory agents for patients unresponsive to first-line options should be individualized based on assessment of overall risks and benefits. These agents include <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> increase the risk of teratogenicity and should not be used in pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications and use of specific medications </strong>– <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">Magnesium sulfate</a> is contraindicated in patients who have MG, since it can precipitate a severe myasthenic crisis  (<a class="graphic graphic_table graphicRef100362" href="/z/d/graphic/100362.html" rel="external">table 2</a>). For management of preeclampsia or eclampsia in patients with MG, severe hypertension can be treated with <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a> or <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>. <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">Levetiracetam</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a> can be used for seizure prophylaxis, whereas <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> can potentially exacerbate weakness and is therefore reserved for refractory seizures. Non-depolarizing muscle relaxants should be avoided. (See <a class="local">'Symptomatic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management during labor </strong>– The second stage of labor may be affected in patients with MG because the voluntary striated muscles used during expulsive efforts may easily weaken. Appropriate steps should be taken to circumvent the effects of maternal fatigue on delivery since stress and exertion can precipitate a myasthenic crisis. During labor, anticholinesterase medications should be administered parenterally to avoid erratic gastrointestinal absorption. (See <a class="local">'Labor and delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring for neonatal MG </strong>– All infants of myasthenic mothers should be observed in a special care nursery for the first 48 to 72 hours of life, as transient neonatal MG develops in 10 to 20 percent of infants born to myasthenic mothers. (See <a class="local">'Neonatal myasthenia gravis'</a> above and  <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">"Neuromuscular junction disorders in newborns and infants", section on 'Neonatal myasthenia gravis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Breastfeeding </strong>– Glucocorticoids can be used safely in lactation. Anticholinesterase drugs are found in breast milk in low levels and are therefore considered safe in lactation unless high doses are required. <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and some other immunotherapeutic agents can cause immunosuppression in the infant and are therefore contraindicated in breastfeeding mothers. (See <a class="local">'Breastfeeding'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Plauché WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 1991; 34:82.</a></li><li><a class="nounderline abstract_t">Varner M. Myasthenia gravis and pregnancy. Clin Obstet Gynecol 2013; 56:372.</a></li><li><a class="nounderline abstract_t">Hamel J, Ciafaloni E. An Update: Myasthenia Gravis and Pregnancy. Neurol Clin 2018; 36:355.</a></li><li><a class="nounderline abstract_t">Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016; 87:419.</a></li><li><a class="nounderline abstract_t">Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002; 104:21.</a></li><li><a class="nounderline abstract_t">Harada Y, Bettin M, Juel VC, et al. Pregnancy in MuSK-positive myasthenia gravis: A single-center case series. Muscle Nerve 2023; 68:85.</a></li><li><a class="nounderline abstract_t">Grover KM, Sripathi N. Myasthenia gravis and pregnancy. Muscle Nerve 2020; 62:664.</a></li><li><a class="nounderline abstract_t">Batocchi AP, Majolini L, Evoli A, et al. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999; 52:447.</a></li><li><a class="nounderline abstract_t">Téllez-Zenteno JF, Hernández-Ronquillo L, Salinas V, et al. Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. BMC Musculoskelet Disord 2004; 5:42.</a></li><li><a class="nounderline abstract_t">Santos E, Braga A, Gabriel D, et al. MuSK myasthenia gravis and pregnancy. Neuromuscul Disord 2018; 28:150.</a></li><li><a class="nounderline abstract_t">Ducci RD, Lorenzoni PJ, Kay CS, et al. Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscul Disord 2017; 27:352.</a></li><li><a class="nounderline abstract_t">Braga AC, Pinto C, Santos E, Braga J. Myasthenia gravis in pregnancy: Experience of a portuguese center. Muscle Nerve 2016; 54:715.</a></li><li><a class="nounderline abstract_t">Toscano M, Thornburg LL. Neurological diseases in pregnancy. Curr Opin Obstet Gynecol 2019; 31:97.</a></li><li><a class="nounderline abstract_t">Scott JS. Immunological diseases in pregnancy. Prog Allergy 1977; 23:321.</a></li><li><a class="nounderline abstract_t">Cheng I, Lin CH, Lin MI, et al. Outcome of myasthenia gravis mothers and their infants. Acta Paediatr Taiwan 2007; 48:141.</a></li><li><a class="nounderline abstract_t">Gveric-Ahmetasevic S, Colić A, Elvedji-Gasparović V, et al. Can neonatal myasthenia gravis be predicted? J Perinat Med 2008; 36:503.</a></li><li><a class="nounderline abstract_t">Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry 2014; 85:538.</a></li><li><a class="nounderline abstract_t">Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007; 14:38.</a></li><li><a class="nounderline abstract_t">Lu CH, Liou CM, Chen YS, et al. Anesthetic management in myasthenic parturient. Ma Zui Xue Za Zhi 1992; 30:193.</a></li><li><a class="nounderline abstract_t">Burke ME. Myasthenia gravis and pregnancy. J Perinat Neonatal Nurs 1993; 7:11.</a></li><li><a class="nounderline abstract_t">Uncu G, Küçükerdogan I, Ozan H, Cengiz C. Pregnancy and myasthenia gravis. A case report. Clin Exp Obstet Gynecol 1995; 22:145.</a></li><li><a class="nounderline abstract_t">Stafford IP, Dildy GA. Myasthenia gravis and pregnancy. Clin Obstet Gynecol 2005; 48:48.</a></li><li><a class="nounderline abstract_t">Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997; 23:149.</a></li><li><a class="nounderline abstract_t">Haugen G, Fauchald P, Sødal G, et al. Pregnancy outcome in renal allograft recipients in Norway. The importance of immunosuppressive drug regimen and health status before pregnancy. Acta Obstet Gynecol Scand 1994; 73:541.</a></li><li><a class="nounderline abstract_t">Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99:443.</a></li><li><a class="nounderline abstract_t">Watson WJ, Katz VL, Bowes WA Jr. Plasmapheresis during pregnancy. Obstet Gynecol 1990; 76:451.</a></li><li><a class="nounderline abstract_t">Gracey DR, Howard FM Jr, Divertie MB. Plasmapheresis in the treatment of ventilator-dependent myasthenia gravis patients. Report of four cases. Chest 1984; 85:739.</a></li><li><a class="nounderline abstract_t">Benshushan A, Rojansky N, Weinstein D. Myasthenia gravis and preeclampsia. Isr J Med Sci 1994; 30:229.</a></li><li><a class="nounderline abstract_t">Piura B. The association of preeclampsia and myasthenia gravis: Double trouble. Isr J Med Sci 1994; 30:243.</a></li><li><a class="nounderline abstract_t">Verspyck E, Mandelbrot L, Dommergues M, et al. Myasthenia gravis with polyhydramnios in the fetus of an asymptomatic mother. Prenat Diagn 1993; 13:539.</a></li><li><a class="nounderline abstract_t">Morel E, Bach JF, Briard ML, Aubry JP. Neonatal myasthenia gravis. Anti-acetylcholine receptor antibodies in the amniotic fluid. J Neuroimmunol 1984; 6:313.</a></li><li><a class="nounderline abstract_t">Carr SR, Gilchrist JM, Abuelo DN, Clark D. Treatment of antenatal myasthenia gravis. Obstet Gynecol 1991; 78:485.</a></li><li><a class="nounderline abstract_t">Banner H, Niles KM, Ryu M, et al. Myasthenia gravis in pregnancy: Systematic review and case series. Obstet Med 2022; 15:108.</a></li><li><a class="nounderline abstract_t">Leventhal SR, Orkin FK, Hirsh RA. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology 1980; 53:26.</a></li><li><a class="nounderline abstract_t">Naguib M, el Dawlatly AA, Ashour M, Bamgboye EA. Multivariate determinants of the need for postoperative ventilation in myasthenia gravis. Can J Anaesth 1996; 43:1006.</a></li><li><a class="nounderline abstract_t">Nitahara K, Sugi Y, Higa K, et al. Neuromuscular effects of sevoflurane in myasthenia gravis patients. Br J Anaesth 2007; 98:337.</a></li><li><a class="nounderline abstract_t">Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 2003; 61:1362.</a></li><li><a class="nounderline abstract_t">Giwa-Osagie OF, Newton JR, Larcher V. Obstetric performance of patients with my asthenia gravis. Int J Gynaecol Obstet 1981; 19:267.</a></li><li><a class="nounderline abstract_t">Wen JC, Liu TC, Chen YH, et al. No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a nationwide population-based study. Eur J Neurol 2009; 16:889.</a></li><li><a class="nounderline abstract_t">Gilhus NE. Myasthenia Gravis Can Have Consequences for Pregnancy and the Developing Child. Front Neurol 2020; 11:554.</a></li></ol></div><div id="topicVersionRevision">Topic 5132 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025979" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myasthenia gravis in mothers and their newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23563874" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Myasthenia gravis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655454" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An Update: Myasthenia Gravis and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27358333" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : International consensus guidance for management of myasthenia gravis: Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12128277" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myasthenia gravis in pregnancy: report on 69 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37150596" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pregnancy in MuSK-positive myasthenia gravis: A single-center case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32929722" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Myasthenia gravis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025772" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Course and treatment of myasthenia gravis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546494" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myasthenia gravis and pregnancy: clinical implications and neonatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305138" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : MuSK myasthenia gravis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28256306" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical follow-up of pregnancy in myasthenia gravis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26930188" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Myasthenia gravis in pregnancy: Experience of a portuguese center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730343" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neurological diseases in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/339232" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Immunological diseases in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17912986" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcome of myasthenia gravis mothers and their infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18681836" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Can neonatal myasthenia gravis be predicted?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757420" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222111" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1302793" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anesthetic management in myasthenic parturient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336287" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Myasthenia gravis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7781182" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pregnancy and myasthenia gravis. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15725856" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Myasthenia gravis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9031380" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Immunosuppressive drug use during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8079604" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pregnancy outcome in renal allograft recipients in Norway. The importance of immunosuppressive drug regimen and health status before pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2365192" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety of azathioprine in pregnancy in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2116612" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Plasmapheresis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6723382" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Plasmapheresis in the treatment of ventilator-dependent myasthenia gravis patients. Report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181923" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myasthenia gravis and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181927" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The association of preeclampsia and myasthenia gravis: Double trouble.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372081" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Myasthenia gravis with polyhydramnios in the fetus of an asymptomatic mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6746895" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neonatal myasthenia gravis. Anti-acetylcholine receptor antibodies in the amniotic fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1870801" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of antenatal myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35845224" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Myasthenia gravis in pregnancy: Systematic review and case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7386905" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prediction of the need for postoperative mechanical ventilation in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896851" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multivariate determinants of the need for postoperative ventilation in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251207" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neuromuscular effects of sevoflurane in myasthenia gravis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638956" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Myasthenia gravis: consequences for pregnancy, delivery, and the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6119253" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Obstetric performance of patients with my asthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19486132" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32595594" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Myasthenia Gravis Can Have Consequences for Pregnancy and the Developing Child.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
